ArticlePloS one2016

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Christoph Schliemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.